Secondary prevention of cardiovascular disease: is it time for the polypill to be standard treatment?
作者信息
Marshall Tom
机构信息
Department of Applied Health Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
出版信息
Lancet Reg Health Eur. 2025 Jul 12;55:101384. doi: 10.1016/j.lanepe.2025.101384. eCollection 2025 Aug.
Abstract
摘要
相似文献
1
Secondary prevention of cardiovascular disease: is it time for the polypill to be standard treatment?心血管疾病的二级预防：复方制剂成为标准治疗的时机到了吗？
Lancet Reg Health Eur. 2025 Jul 12;55:101384. doi: 10.1016/j.lanepe.2025.101384. eCollection 2025 Aug.
2
Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial.西班牙心血管多效药丸策略与标准治疗用于二级心血管预防的成本效益：基于SECURE试验的分析
Lancet Reg Health Eur. 2025 Jun 27;55:101348. doi: 10.1016/j.lanepe.2025.101348. eCollection 2025 Aug.
3
Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.复方药在心血管疾病一级和二级预防中的药物依从性的益处：系统评价。
Vasc Health Risk Manag. 2023 Sep 12;19:605-615. doi: 10.2147/VHRM.S421024. eCollection 2023.
4
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population.在服务不足人群中使用复方制剂预防心血管疾病的成本效益
JAMA Cardiol. 2025 Mar 1;10(3):224-233. doi: 10.1001/jamacardio.2024.4812.
5
Efficacy and Safety of a Polypill to Reduce Cardiovascular Events: A Review of Clinical Trials.复方药降低心血管事件的疗效和安全性：临床试验综述。
J Cardiovasc Pharmacol. 2024 Jan 1;83(1):8-15. doi: 10.1097/FJC.0000000000001508.
6
A systematic review and economic evaluation of statins for the prevention of coronary events.他汀类药物预防冠状动脉事件的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140.
7
Efficacy of different polypill combinations for primary and secondary cardiovascular disease prevention: a systematic review and meta-analysis.不同复方制剂组合用于原发性和继发性心血管疾病预防的疗效：一项系统评价和荟萃分析。
Front Cardiovasc Med. 2025 Jun 9;12:1558579. doi: 10.3389/fcvm.2025.1558579. eCollection 2025.
8
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.减少或无麸质饮食对心血管疾病一级预防的影响。
Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2.
10
Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.成人及儿童中与HIV感染相关的口腔念珠菌病的预防及管理干预措施。
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003940. doi: 10.1002/14651858.CD003940.pub3.
本文引用的文献
1
Cost-effectiveness of the CV-polypill strategy versus standard care for secondary cardiovascular prevention in Spain: an analysis based on the SECURE trial.西班牙心血管多效药丸策略与标准治疗用于二级心血管预防的成本效益：基于SECURE试验的分析
Lancet Reg Health Eur. 2025 Jun 27;55:101348. doi: 10.1016/j.lanepe.2025.101348. eCollection 2025 Aug.
2
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population.在服务不足人群中使用复方制剂预防心血管疾病的成本效益
JAMA Cardiol. 2025 Mar 1;10(3):224-233. doi: 10.1001/jamacardio.2024.4812.
3
Adoption and scale-up of the cardiovascular Polypill: a realist institutional analysis.采用和推广心血管复方药：一个实际的制度分析。
Health Policy Plan. 2023 Jan 6;38(1):15-27. doi: 10.1093/heapol/czac088.
4
Polypill Strategy in Secondary Cardiovascular Prevention.复方药治疗在二级心血管预防中的应用。
N Engl J Med. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. Epub 2022 Aug 26.
5
Polypill for Cardiovascular Disease Prevention in an Underserved Population.用于服务不足人群心血管疾病预防的复方药。
N Engl J Med. 2019 Sep 19;381(12):1114-1123. doi: 10.1056/NEJMoa1815359.
6
Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.固定剂量复方制剂（复方药）在印度心血管疾病二级预防中的成本效益：UMPIRE 试验的试验内成本效益分析。
Int J Cardiol. 2018 Jul 1;262:71-78. doi: 10.1016/j.ijcard.2018.03.082. Epub 2018 Mar 21.
7
Patient preferences for a polypill for the prevention of cardiovascular diseases.患者对用于预防心血管疾病的多效药丸的偏好。
Ann Pharmacother. 2015 May;49(5):528-39. doi: 10.1177/1060028015570468. Epub 2015 Feb 13.
8
Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials.监测基于血管紧张素转换酶抑制剂方案的初始反应：来自随机、安慰剂对照试验的个体患者数据荟萃分析。
Hypertension. 2010 Sep;56(3):533-9. doi: 10.1161/HYPERTENSIONAHA.110.152421. Epub 2010 Jul 12.
9
Monitoring cholesterol levels: measurement error or true change?监测胆固醇水平：测量误差还是真实变化？
Ann Intern Med. 2008 May 6;148(9):656-61. doi: 10.7326/0003-4819-148-9-200805060-00005.
10
A strategy to reduce cardiovascular disease by more than 80%.一种将心血管疾病减少80%以上的策略。
BMJ. 2003 Jun 28;326(7404):1419. doi: 10.1136/bmj.326.7404.1419.
Zotero 插件